SaddlePoint Mosaics
Conditions
-
All prices are in Euro (€), and exclusive of 21% value added tax (VAT)
-
Single-user trial licenses are only available for Windows builds
-
All other licenses are available for Windows, UNIX/LINUX and MacOS platforms
-
Collaborator licenses are available to partners in formal research collaborations with Saddle Point Science Europe BV, of which results are to be published under joint authorship
-
Students enrolled at degree-awarding institutions can purchase single-user licenses only, proof of student status (e.g. copy of a university ID card) will be required
-
Support includes:
-
one-to-one installation
-
demonstration/introduction (on-site or remotely)
-
software support
-
results interpretation (remotely)
-
-
Software manuals are made available as electronic (PDF) documents
-
SaddlePoint DatasetManager included in all packages (Free of charge)
Features
per user
License type | Duration | Support | Manual | Multi-core |
|---|---|---|---|---|
Trial | 2 months | ─ | ✓ | ✓ |
Student | 1 year | ✓ | ✓ | ─ |
Collaborator | 1 year | ✓ | ✓ | ✓ |
Public sector | 1 year | ✓ | ✓ | ✓ |
Commercial | 1 year | ✓ | ✓ | ✓ |
Costs
per user
License type | Duration | 1 user | 2 users | Additional users |
|---|---|---|---|---|
Trial | 2 months | free | ─ | ─ |
Student | 1 year | € 1.100,00 | ─ | ─ |
Collaborator | 1 year | € 7.800,00 | € 11.700,00 | €2.600,00 each |
Public sector | 1 year | € 14.500,00 | € 21.750,00 | €4.380,00 each |
Commercial | 1 year | € 19.600,00 | € 29.400,00 | €6.530,00 each |
Publications in which the pipeline was used
-
-
Häggström, C., Rowley, M., Liedberg, F., Coolen, A. C. C., & Holmberg, L. (2023). Latent heterogeneity of muscle‐invasive bladder cancer in patient characteristics and survival: A population‐based nation‐wide study in the Bladder Cancer Data Base Sweden (BladderBaSe). Cancer Medicine, 12(12), 13856–13864. https://doi.org/10.1002/cam4.5981
-
Barber, P. R., Weitsman, G., Lawler, K., Barrett, J. E., Rowley, M., Rodríguez-Justo, M., Fisher, D. J., Gao, F., Tullis, I. D. C., Deng, J., Brown, L., Kaplan, R., Hochhauser, D., Adams, R., Maughan, T., Vojnovic, B., Coolen, A. C. C., & Ng, T. (2019). HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. JNCI: Journal Of The National Cancer Institute, 112(9), 944–954. https://doi.org/10.1093/jnci/djz231
-
Häggström, C., Van Hemelrijck, M., Garmo, H., Robinson, D., Stattin, P., Rowley, M., Coolen, A. C. C., & Holmberg, L. (2018). Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus. International Journal Of Cancer, 143(8), 1868–1875. https://doi.org/10.1002/ijc.31587
-
Rowley, M., Garmo, H., Van Hemelrijck, M., Wulaningsih, W., Grundmark, B., Zethelius, B., Hammar, N., Walldius, G., Inoue, M., Holmberg, L., & Coolen, A. C. C. (2017). A latent class model for competing risks. Statistics in Medicine, 36(13), 2100–2119. https://doi.org/10.1002/sim.7246
-
Wulaningsih, W., Vahdaninia, M., Rowley, M., Holmberg, L., Garmo, H., Malmström, H., Lambe, M., Hammar, N., Walldius, G., Jungner, I., Coolen, A. C. C., & Van Hemelrijck, M. (2015). Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 15(1). https://doi.org/10.1186/s12885-015-1928-z
-